119 related articles for article (PubMed ID: 841675)
1. In vivo stability of cryoprecipitate fibrinogen.
Sherman LA
Transfusion; 1977; 17(1):59-61. PubMed ID: 841675
[TBL] [Abstract][Full Text] [Related]
2. Cryoprecipitate as a reliable source of fibrinogen replacement.
Ness PM; Perkins HA
JAMA; 1979 Apr; 241(16):1690-1. PubMed ID: 430729
[TBL] [Abstract][Full Text] [Related]
3. A rapidly produced 125I labelled autologous fibrinogen: in vitro properties and preliminary metabolic studies in man.
Hawker RJ; Hawker LM
J Clin Pathol; 1976 Jun; 29(6):495-501. PubMed ID: 939805
[TBL] [Abstract][Full Text] [Related]
4. Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20-24°C for up to 24 h.
Sheffield WP; Bhakta V; Jenkins C
Vox Sang; 2016 Jan; 110(1):12-9. PubMed ID: 26178178
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen content of low-volume cryoprecipitate.
Hoffman M; Koepke JA; Widmann FK
Transfusion; 1987; 27(4):356-8. PubMed ID: 3111036
[TBL] [Abstract][Full Text] [Related]
6. Postthaw stability of fibrinogen in cryoprecipitate stored between 1 and 6 degrees C.
Howard PL; Bovill EG; Golden E
Transfusion; 1991 Jan; 31(1):30-1. PubMed ID: 1898785
[TBL] [Abstract][Full Text] [Related]
7. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
Aufderheide WM; Skinner SF; Kaneko JJ
Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
[TBL] [Abstract][Full Text] [Related]
8. Comparison of iodine monochloride and modified chloramine-T radioiodination for in vivo protein studies.
Lee J; Coleman RE; Sherman LA
J Lab Clin Med; 1977 Apr; 89(4):836-44. PubMed ID: 845483
[TBL] [Abstract][Full Text] [Related]
9. The relationship between fibrinogen degradation products and cryofibrinogen.
Komp DM; Donaldson MH
Am J Pediatr Hematol Oncol; 1979; 1(2):99-102. PubMed ID: 543513
[TBL] [Abstract][Full Text] [Related]
10. Recovery of fibrinogen in cryoprecipitate pasteurized in the presence of sucrose and glycine.
Reis FM; de-Koning B; Das PC; Smit-Sibinga CT
Braz J Med Biol Res; 1993 May; 26(5):473-6. PubMed ID: 8257936
[TBL] [Abstract][Full Text] [Related]
11. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
Pereira A
Haematologica; 2007 Jun; 92(6):846-9. PubMed ID: 17550860
[TBL] [Abstract][Full Text] [Related]
12. Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: a comparative study.
Marshall S
J Urol; 1978 Mar; 119(3):310-1. PubMed ID: 642080
[TBL] [Abstract][Full Text] [Related]
13. A critical evaluation of cryoprecipitate for replacement of fibrinogen.
Sørensen B; Bevan D
Br J Haematol; 2010 Jun; 149(6):834-43. PubMed ID: 20456356
[TBL] [Abstract][Full Text] [Related]
14. Extraction, radioiodination, and in vivo catabolism of equine fibrinogen.
Coyne CP; Hornof WJ; Kelly AB; O'Brien TR; DeNardo SJ
Am J Vet Res; 1985 Dec; 46(12):2572-7. PubMed ID: 4083596
[TBL] [Abstract][Full Text] [Related]
15. Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.
Smith KJ; Hodges PA
Transfusion; 1984; 24(6):520-3. PubMed ID: 6438840
[TBL] [Abstract][Full Text] [Related]
16. Evidence that low molecular fibrinogen (LMW) is formed in man by degradation of high molecular weight fibrinogen (HMW).
Holm B; Nilsen DW; Godal HC
Thromb Res; 1986 Mar; 41(6):879-84. PubMed ID: 3705020
[No Abstract] [Full Text] [Related]
17. Fibrinogen in cryoprecipitate and its relationship to factor VIII (AHF) levels.
Ness PM; Perkins HA
Transfusion; 1980; 20(1):93-6. PubMed ID: 7355478
[TBL] [Abstract][Full Text] [Related]
18. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
[TBL] [Abstract][Full Text] [Related]
19. Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposure.
Hoffman M; Jenner P
Am J Clin Pathol; 1990 May; 93(5):694-7. PubMed ID: 2327369
[TBL] [Abstract][Full Text] [Related]
20. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
